| GOVERNMENT
OF INDIA
MINISTRY OF SCIENCE AND TECHNOLOGY
DEPARTMENT OF SCIENCE AND TECHNOLOGY
LOK SABHA
UNSTARRED QUESTION NO. 4361
TO BE ANSWERED ON 19.5.2006 LOAN
TO PHARMA COMPANIES 4361. SHRI MOHD. MUKEEM:
Will the Minister
of SCIENCE AND TECHNOLOGY
be pleased to refer to the reply given to Unstarred
Question No. 2191 dated March 10, 2006 and state: (a) the names of these
six companies and the amount of loan given to each company indicating the details
of the project for Research and Development;
(b) the progress in R&D project
of these companies since the time of disbursal of loan;
(c) the time by which
the loan is likely to be recovered from these companies; and
(d) the details
of amount repaid by each company and steps taken to recover the balance amount? A
N S W E R MINISTER OF SCIENCE AND TECHNOLOGY AND MINISTER OF OCEAN DEVELOPMENT (KAPIL
SIBAL)
(a) The names of six companies as mentioned in
Lok Sabha unstarred Q No.2191, dated March 10, 2006 and the amount of loan to
each of them indicating the details of the project for Research & Development
are given below:
Sl.
No. | Name of the company | Amount
of Loan released in 2004-05 (Rs. in Lakhs) | Project
Details | | 1. | Dabur Research Foundation (DRF),
Ghaziabad | 200.00 | Clinical Development of DRF 7295 in advanced
and metastatic cancers of the gastrointestinal tract (colon, pancreas and stomach)
and lung (non small cell) | | 2. | Promed Exports Pvt. Ltd.,
New Delhi | 200.00 | Formulation development, stability studies, pre-clinical
and clinical studies of anti-cataract eye drops for applying the technology and
innovation in effective prevention and treatment of cataract. | | 3. | Intas
Pharmaceuticals Ltd., Ahmedabad | 200.00 | Formulation research and
development of protein based therapeutics for human use | | 4. | Biological
E. Ltd., Hyderabad | 275.00 | Development of a tetravalent dengue
vaccine by using a combination of 30 deletion mutant and chemeric constructs of
DEN-1, DEN-2, DEN-3 and DEN-4 viruses against dengue virus infection | | 5. | Dalmia
Centre for R&D, Coimbatore | 25.00 | Development of quality
controlled plant based formulation in the treatment of dementia and its validation
with reference to its safety and efficacy | | 6. | Lupin Ltd.,
Mumbai | 375.00 | Latent M.tuberculosis : New targets, drug delivery
system, bio enhancer and therapeutics
| | | Total |
1275.00 | |
(b) to (d): All these six projects
have been monitored by the monitoring committees constituted separately for each
project and the progress of these R&D projects has been reported to be satisfactory.
Each project has different duration ranging from 2 to 3 years. As per the terms
and conditions of the loan, the repayment will commence after the project period
and the total amount including interest will be recovered in 10 annual instalments.
Since these projects are ongoing, repayment of loan has not begun.
| 
Introduction
Parliament Unit